{
  "id": "more-chinese-biotechs-challenge-glp-1-dominance-in-diabetes",
  "title": "More Chinese biotechs challenge GLP-1 dominance in diabetes",
  "summary": "More Chinese drugmakers are moving beyond GLP-1s, adopting new strategies to capture a larger share of the global diabetes market. GLP-1 drugs have become the face of modern diabetes care. They work, they scale and they’ve turned companies like Novo Nordisk into global powerhouses. But for all their success, they also reflect a familiar logic: […] The post More Chinese biotechs challenge GLP-1 dominance in diabetes appeared first on Longevity.Technology.",
  "url": "https://longevity.technology/news/more-chinese-biotechs-challenge-glp-1-dominance-in-diabetes/",
  "source": "Longevity.Technology",
  "author": "Kyle Umipig",
  "category": "news",
  "publishedAt": "2026-01-28T13:45:58.000Z",
  "fetchedAt": "2026-02-04T10:49:05.821Z",
  "relevanceScore": 0.2,
  "matchedKeywords": [
    "longevity"
  ],
  "relatedProducts": [],
  "type": "web",
  "savedAt": "2026-02-04T10:49:05.894Z"
}